Altimmune ((ALT)) announced an update on their ongoing clinical study.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Study Overview: The RECLAIM STUDY is a Phase 2 clinical trial conducted by Altimmune, Inc., aimed at evaluating the efficacy and safety of pemvidutide in treating Alcohol Use Disorder (AUD) in individuals with obesity or overweight. This study is significant as it explores a potential new treatment avenue for a condition that affects a substantial portion of the population.
Intervention/Treatment: The study tests pemvidutide, a drug administered as a 2.4 mg subcutaneous injection once weekly, against a placebo. Pemvidutide is intended to reduce symptoms of AUD in the target population.
Study Design: This interventional study is randomized and employs a parallel assignment model. It is double-blind, meaning participants, care providers, investigators, and outcomes assessors are unaware of which treatment participants receive. The primary goal is treatment-focused.
Study Timeline: The study began on May 16, 2025, with the latest update submitted on June 10, 2025. These dates are crucial as they indicate the study’s current recruiting status and the timeline for potential results.
Market Implications: This update could positively influence Altimmune’s stock performance by showcasing its commitment to innovative treatments. The study’s success might enhance investor confidence and position Altimmune favorably against competitors in the pharmaceutical industry.
The study is currently ongoing, with further details available on the ClinicalTrials portal.